See more : Götenehus Group AB (publ) (GHUS-B.ST) Income Statement Analysis – Financial Results
Complete financial analysis of TWi Biotechnology, Inc. (6610.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TWi Biotechnology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- F-Tech Inc. (7212.T) Income Statement Analysis – Financial Results
- Daiki Aluminium Industry Co., Ltd. (5702.T) Income Statement Analysis – Financial Results
- OCI N.V. (OCINF) Income Statement Analysis – Financial Results
- Sonos, Inc. (0ZFN.L) Income Statement Analysis – Financial Results
- Allcargo Terminals Limited (ATL.BO) Income Statement Analysis – Financial Results
TWi Biotechnology, Inc. (6610.TWO)
About TWi Biotechnology, Inc.
TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; and AC- 1101, which is in Phase 1 trial for the treatment of vitiligo and preclinical stage for the treatment of atopic dermatitis, as well as granuloma annulare and rare autoimmune skin diseases. It has a drug development agreement with Hong Kong Winhealth Pharma Group Co., Limited. in Mainland China, Hong Kong, and Macao markets. TWi Biotechnology, Inc. was founded in 2010 and is based in Taipei, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 66.40M | 1.25M | 9.66M |
| Cost of Revenue | 9.74M | 0.00 | 913.00K | 1.04M | 7.31M |
| Gross Profit | -9.74M | 0.00 | 65.48M | 203.00K | 2.36M |
| Gross Profit Ratio | 0.00% | 0.00% | 98.62% | 16.29% | 24.39% |
| Research & Development | 148.41M | 74.56M | 66.66M | 84.99M | 97.00M |
| General & Administrative | 21.15M | 15.62M | 14.12M | 13.77M | 19.29M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 21.15M | 15.62M | 14.12M | 13.77M | 19.29M |
| Other Expenses | 0.00 | 12.37M | -1.32M | -5.40M | 0.00 |
| Operating Expenses | 169.56M | 90.18M | 80.79M | 98.76M | 117.52M |
| Cost & Expenses | 169.56M | 90.18M | 81.70M | 99.80M | 124.83M |
| Interest Income | 2.83M | 1.67M | 1.41M | 3.47M | 3.71M |
| Interest Expense | 87.00K | 48.00K | 86.00K | 20.00K | 68.00K |
| Depreciation & Amortization | 9.74M | 10.35M | 11.10M | 11.67M | 7.96M |
| EBITDA | -160.86M | -65.78M | -4.11M | -88.82M | -100.47M |
| EBITDA Ratio | 0.00% | 0.00% | -6.19% | -7,128.01% | -1,096.61% |
| Operating Income | -169.56M | -76.13M | -15.21M | -100.49M | -113.94M |
| Operating Income Ratio | 0.00% | 0.00% | -22.91% | -8,064.77% | -1,179.01% |
| Total Other Income/Expenses | -1.13M | 14.00M | 4.00K | -1.95M | 2.42M |
| Income Before Tax | -170.68M | -76.18M | -15.30M | -100.51M | -111.52M |
| Income Before Tax Ratio | 0.00% | 0.00% | -23.04% | -8,066.37% | -1,154.01% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 1.35M | 0.00 |
| Net Income | -170.68M | -76.18M | -15.30M | -101.86M | -111.52M |
| Net Income Ratio | 0.00% | 0.00% | -23.04% | -8,174.80% | -1,154.01% |
| EPS | -2.33 | -1.13 | -0.22 | -1.45 | -1.59 |
| EPS Diluted | -2.33 | -1.13 | -0.22 | -1.45 | -1.59 |
| Weighted Avg Shares Out | 73.18M | 67.43M | 70.22M | 70.22M | 70.22M |
| Weighted Avg Shares Out (Dil) | 73.18M | 67.43M | 70.22M | 70.22M | 70.22M |
Source: https://incomestatements.info
Category: Stock Reports